肝素诱导血小板减少症
肝素
血小板因子4
医学
无症状的
血栓形成
血小板
发病机制
免疫学
抗体
重症监护医学
内科学
作者
Gowthami M. Arepally,Thomas L. Ortel
标识
DOI:10.1146/annurev.med.042808.171814
摘要
Heparin-induced thrombocytopenia (HIT) is an immune-mediated hypercoagulable disorder caused by antibodies to platelet factor 4 (PF4) and heparin. HIT develops in temporal association with heparin therapy and manifests either as an unexplained thrombocytopenia or thrombocytopenia complicated by thrombosis. The propensity for thrombosis distinguishes HIT from other common drug-induced thrombocytopenias. Diagnosing HIT in hospitalized patients is often challenging because of the frequency of heparin use, occurrence of thrombocytopenia from other causes, and development of asymptomatic PF4/heparin antibodies in patients treated with heparin. This review summarizes our current understanding of the pathogenesis, clinical features, diagnostic criteria, and management approaches in HIT.
科研通智能强力驱动
Strongly Powered by AbleSci AI